Results 11 to 20 of about 114,702 (262)

Second-generation inhibitors of Bruton tyrosine kinase [PDF]

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
doaj   +3 more sources

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. [PDF]

J Immunother Cancer, 2020
Background The immunosuppressive desmoplastic stroma of pancreatic cancer represents a major hurdle to developing an effective immune response. Preclinical studies in pancreatic cancer have demonstrated promising anti-tumor activity with Bruton tyrosine ...
Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A.   +14 more
europepmc   +2 more sources

The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2020
Objective To assess whether neuropathy with anti-myelin-associated glycoprotein (MAG) antibody may improve after treatment with ibrutinib, an oral inhibitor of Bruton tyrosine kinase, we prospectively treated with ibrutinib a cohort of 3 patients with ...
Castellani F, Visentin A, Campagnolo M, Salvalaggio A, Cacciavillani M, Candiotto C, Bertorelle R, Trentin L, Briani C.   +8 more
europepmc   +2 more sources

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Efficacy and Mechanism Evaluation
Background Chronic lymphocytic leukaemia is the most common leukaemia subtype and associated with profound immunosuppression. Bruton Tyrosine Kinase inhibitors have revolutionised chronic lymphocytic leukaemia management; however, Bruton Tyrosine Kinase ...
Jonathan A Cook, Piers Patten, Nicholas Peckham, Paul Moss, Abhishek Abhishek, Vicki S Barber, Anne Francis, Lelia Duley, Robbert Hoogeboom, Brian J Willett, Gratian Vandici, Gareth Plested, Lucy Eldridge, Patrick Julier, Thomas Roberts, Marie Hodges, Helen M Parry   +16 more
doaj   +2 more sources

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

Clinical Hematology International, 2022
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh, Hassan Abushukair, Aref Qarqash, Sebawe Syaj, Samer Al Hadidi   +4 more
doaj   +5 more sources

Pituitary macroadenoma apoplexy as a rare complication of Bruton tyrosine kinase inhibitor in chronic lymphoid leukaemia [PDF]

Chinese Neurosurgical Journal, 2023
Background Pituitary apoplexy is a neurosurgical emergency and is a known yet rare complication of pituitary macroadenoma. Patients typically present with visual field defects, headache and altered sensorium.
Aysha Gomaa, Robert Skelly
doaj   +2 more sources

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia [PDF]

eJHaem
Introduction Bruton tyrosine kinase inhibitors (BTKi) are highly effective therapy for chronic lymphocytic leukemia (CLL) but can lead to long‐term side effects.
Benjamin Heyman, Michael Choi, Thomas J. Kipps   +2 more
doaj   +2 more sources

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. [PDF]

Haematologica, 2019
Mantle cell lymphoma (MCL), an aggressive B-cell malignancy accounting for 6% of non-Hodgkin lymphomas, remains incurable with standard therapy. Despite the approval of bortezomib,[1][1] temsirolimus,[2][2] lenalidomide,[3][3] ibrutinib[4][4] and ...
Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP.   +11 more
europepmc   +2 more sources

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. [PDF]

Oncotarget, 2017
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia.
Wu J, Zhang M, Liu D.
europepmc   +2 more sources

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies [PDF]

Cancer Medicine
Introduction Blastoid variant‐mantle cell lymphoma (BV‐MCL) represents an aggressive subset of patients with no established standard of care treatment approach. Methods We performed a retrospective analysis of the clinical characteristics and outcomes of
Benjamin J. Lee, Jenny Liu, Shawn P. Griffin, Jean Doh, Stefan O. Ciurea, Piyanuch Kongtim, Elizabeth A. Brem   +6 more
doaj   +2 more sources